{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T16:57:56Z","timestamp":1782752276211,"version":"3.54.5"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Thrombotic microangiopathy is a pathological condition comprised of microvascular thrombosis involving any organ of the body leading to thrombocytopenia, Coombs-negative hemolytic anemia, and end-organ damage. The most common forms of thrombotic microangiopathies are Shiga toxin-producing <jats:italic>Escherichia coli<\/jats:italic>-mediated hemolytic uremic syndrome, thrombotic thrombocytopenic purpura, and atypical hemolytic uremic syndrome. The atypical hemolytic uremic syndrome occurs due to genetic and acquired mutations in complement regulatory factors and to complement activation factors in the immune system, mainly the alternative pathway. Clinical manifestations and outcomes differ with the prevalent mutations of the patient. Currently, available treatment modalities are therapeutic plasma exchange and a monoclonal antibody against C5, eculizumab. We report a case of a Sri Lankan girl diagnosed with atypical hemolytic uremic syndrome complicated with septicemia, hemolytic anemia, acute kidney injury, pulmonary hemorrhage with respiratory failure, and hypertension who had a complete remission following long-term (30 months) therapeutic plasma exchange.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>A 15-year-old Sri Lankan girl was transferred from a local hospital with the features of septicemia and acute kidney injury for specialized management. She had high blood pressure (180\/100\u2009mmHg) on admission. She underwent appendicectomy based on suspicion of acute appendicitis as the cause of sepsis. Following surgery, her condition deteriorated, and intensive care unit management was warranted because she developed pulmonary hemorrhages and respiratory failure requiring mechanical ventilation and renal replacement therapy in the form of hemodialysis. Her blood investigations showed microangiopathic hemolytic anemia, thrombocytopenia, elevated lactate dehydrogenase, and reduced human complement C3 levels, together with a normal coagulation profile. She was diagnosed with atypical hemolytic uremic syndrome and was initiated on therapeutic plasma exchange and other supportive therapy, including corticosteroids. Following a lengthy course of plasma exchange, complete recovery was achieved.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>The atypical hemolytic uremic syndrome is a rare disease entity requiring a high index of suspicion to diagnose. It is a diagnosis of exclusion. Early diagnosis with prompt treatment will render a better outcome. The atypical hemolytic uremic syndrome needs to be considered in all patients with thrombotic microangiopathy.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13256-019-2334-y","type":"journal-article","created":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T01:02:40Z","timestamp":1578877360000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Atypical hemolytic uremic syndrome: a case report"],"prefix":"10.1186","volume":"14","author":[{"given":"B. M. D. B.","family":"Basnayake","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. W. M.","family":"Wazil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Nanayakkara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. M. D. K.","family":"Samarakoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. M. S. K.","family":"Senavirathne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. U. E. W. D. R.","family":"Thangarajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Karunasena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. M. B. S. S.","family":"Mahanama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,13]]},"reference":[{"issue":"2","key":"2334_CR1","doi-asserted-by":"publisher","first-page":"300","DOI":"10.2215\/CJN.00620117","volume":"13","author":"V Brocklebank","year":"2018","unstructured":"Brocklebank V, Wood KM, Kavanagh D. Thrombotic microangiopathy and the kidney. Clin J Am Soc Nephrol. 2018;13(2):300\u201317.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"2334_CR2","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/MNH.0b013e3283378f25","volume":"19","author":"K Benz","year":"2010","unstructured":"Benz K, Amann K. Thrombotic microangiopathy: new insights. Curr Opin Nephrol Hypertens. 2010;19(3):242\u20137.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"3","key":"2334_CR3","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","volume":"91","author":"TH Goodship","year":"2017","unstructured":"Goodship TH, Cook HT, Fachouri F, Fervenza FC, Fremeaux-Bacchi V, Kavanagh D, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference. Kidney Int. 2017;91(3):539\u201351.","journal-title":"Kidney Int"},{"issue":"2","key":"2334_CR4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.5551\/jat.RV17026","volume":"26","author":"Y Yoshida","year":"2019","unstructured":"Yoshida Y, Kato H, Ikeda Y, Nangaku M. Pathogenesis of atypical hemolytic uremic syndrome. J Atheroscler Thromb. 2019;26(2):99\u2013110.","journal-title":"J Atheroscler Thromb"},{"key":"2334_CR5","doi-asserted-by":"publisher","first-page":"3653","DOI":"10.1182\/blood-2010-02-271957","volume":"116","author":"J Huang","year":"2010","unstructured":"Huang J, Motto DG, Bundle DR, Sadler JE. Shiga toxin B subunits induce VWF secretion by human endothelial cells and thrombotic microangiopathy in ADAMTS13-deficient mice. Blood. 2010;116:3653\u20139.","journal-title":"Blood"},{"issue":"1","key":"2334_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/microorganisms7010015","volume":"7","author":"S Buelli","year":"2019","unstructured":"Buelli S, Zoja C, Remuzzi G, Morigi M. Complement activation contributes to the pathophysiology of Shiga toxin-associated hemolytic uremic syndrome. Microorganisms. 2019;7(1):15.","journal-title":"Microorganisms"},{"issue":"6","key":"2334_CR7","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.semnephrol.2013.08.003","volume":"33","author":"D Kavanagh","year":"2013","unstructured":"Kavanagh D, Goodship TH, Richards A. Atypical hemolytic uremic syndrome. Semin Nephrol. 2013;33(6):508\u201330.","journal-title":"Semin Nephrol"},{"key":"2334_CR8","first-page":"257","volume":"6","author":"NS Merle","year":"2015","unstructured":"Merle NS, Noe R, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, Roumenina LT. Complement system part II: role in immunity. Front Immunol. 2015;6:257.","journal-title":"Front Immunol"},{"issue":"3","key":"2334_CR9","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10238-018-0491-8","volume":"18","author":"E \u0141ukawska","year":"2018","unstructured":"\u0141ukawska E, Polcyn-Adamczak M, Niemir ZI. The role of the alternative pathway of complement activation in glomerular diseases. Clin Exp Med. 2018;18(3):297\u2013318.","journal-title":"Clin Exp Med"},{"issue":"17","key":"2334_CR10","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJMra0902814","volume":"361","author":"M Noris","year":"2009","unstructured":"Noris M, Remuzzi G. Atypical hemolytic\u2013uremic syndrome. N Engl J Med. 2009;361(17):1676\u201387.","journal-title":"N Engl J Med"},{"issue":"3","key":"2334_CR11","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.4049\/jimmunol.176.3.1305","volume":"176","author":"JM Thurman","year":"2006","unstructured":"Thurman JM, Holers VM. The central role of the alternative complement pathway in human disease. J Immunol. 2006;176(3):1305\u201310.","journal-title":"J Immunol"},{"issue":"13","key":"2334_CR12","doi-asserted-by":"publisher","first-page":"4948","DOI":"10.1182\/blood-2008-01-133702","volume":"112","author":"V Fr\u00e9meaux-Bacchi","year":"2008","unstructured":"Fr\u00e9meaux-Bacchi V, Miller EC, Liszewski MK, Strain L, Blouin J, Brown AL, et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood. 2008;112(13):4948\u201352.","journal-title":"Blood."},{"key":"2334_CR13","doi-asserted-by":"publisher","first-page":"10996","DOI":"10.1073\/pnas.93.20.10996","volume":"93","author":"AK Sharma","year":"1996","unstructured":"Sharma AK, Pangburn MK. Identification of three physically and functionally distinct binding sites for C3b in human complement factor H by deletion mutagenesis. Proc Natl Acad Sci U S A. 1996;93:10996\u20131001.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2334_CR14","doi-asserted-by":"crossref","first-page":"27657","DOI":"10.1074\/jbc.M002903200","volume":"275","author":"TS Jokiranta","year":"2000","unstructured":"Jokiranta TS, Hellwage J, Koistinen V, Zipfel PF, Meri S. Each of the three binding sites on complement factor H interacts with a distinct site on C3b. J Biol Chem. 2000;275:27657\u201362.","journal-title":"J Biol Chem"},{"key":"2334_CR15","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.2215\/CJN.02210310","volume":"5","author":"M Noris","year":"2010","unstructured":"Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, et al. A relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5:1844\u201359.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2334_CR16","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.molimm.2007.05.004","volume":"45","author":"D Kavanagh","year":"2008","unstructured":"Kavanagh D, Richards A, Noris M, Hauhart R, Liszewski MK, Karpman D, et al. Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. Mol Immunol. 2008;45:95\u2013105.","journal-title":"Mol Immunol"},{"key":"2334_CR17","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.molimm.2006.07.004","volume":"44","author":"A Richards","year":"2007","unstructured":"Richards A, Kathryn Liszewski M, Kavanagh D, Fang CJ, Moulton E, Fremeaux-Bacchi V, et al. Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. Mol Immunol. 2007;44:111\u201322.","journal-title":"Mol Immunol"},{"key":"2334_CR18","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1182\/blood-2009-05-221549","volume":"115","author":"I Moore","year":"2010","unstructured":"Moore I, Strain L, Pappworth I, Kavanagh D, Barlow PN, Herbert AP, et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood. 2010;115:379\u201387.","journal-title":"Blood"},{"issue":"5","key":"2334_CR19","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1007\/s10157-018-1549-3","volume":"22","author":"M Fujisawa","year":"2018","unstructured":"Fujisawa M, Kato H, Yoshida Y, Usui T, Takata M, Fujimoto M, et al. Clinical characteristics and genetic backgrounds of Japanese patients with atypical hemolytic uremic syndrome. Clin Exp Nephrol. 2018;22(5):1088\u201399.","journal-title":"Clin Exp Nephrol"},{"key":"2334_CR20","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1073\/pnas.0603420103","volume":"104","author":"E Goicoechea de Jorge","year":"2007","unstructured":"Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J, Carreras L, Arranz EA, Garrido CA, et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci U S A. 2007;104:240\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2334_CR21","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJMoa0810739","volume":"361","author":"M Delvaeye","year":"2009","unstructured":"Delvaeye M, Noris M, De Vriese A, Esmon CT, Esmon NL, Ferrell G, et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361:345\u201357.","journal-title":"N Engl J Med"},{"key":"2334_CR22","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/ng.2590","volume":"45","author":"M Lemaire","year":"2013","unstructured":"Lemaire M, Fremeaux-Bacchi V, Schaefer F, Choi M, Tang WH, Le Quintrec M, et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet. 2013;45:531\u20136.","journal-title":"Nat Genet"},{"issue":"1","key":"2334_CR23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1681\/ASN.2013050453","volume":"25","author":"F Bu","year":"2014","unstructured":"Bu F, Maga T, Meyer NC, Wang K, Thomas CP, Nester CM, et al. Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2014;25(1):55\u201364.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"2334_CR24","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1182\/blood-2005-10-007252","volume":"108","author":"J Caprioli","year":"2006","unstructured":"Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006;108(4):1267\u201379.","journal-title":"Blood"},{"issue":"11","key":"2334_CR25","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1007\/s00467-008-0872-4","volume":"23","author":"C Loirat","year":"2008","unstructured":"Loirat C, Noris M, Fremeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2008;23(11):1957\u201372.","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"2334_CR26","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00467-008-0964-1","volume":"24","author":"G Ariceta","year":"2009","unstructured":"Ariceta G, Besbas N, Johnson S, Karpman D, Landau D, Licht C, et al. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol. 2009;24(4):687\u201396.","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"2334_CR27","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1053\/j.ajkd.2008.07.038","volume":"53","author":"M Michael","year":"2009","unstructured":"Michael M, Elliott EJ, Craig JC, Ridley G, Hodson EM. Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials. Am J Kidney Dis. 2009;53(2):259\u201372.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"2334_CR28","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1093\/ndt\/gfn063","volume":"23","author":"T Kwon","year":"2008","unstructured":"Kwon T, Dragon-Durey MA, Macher MA, Baudouin V, Maisin A, Peuchmaur M, et al. Successful pre-transplant management of a patient with anti-factor H autoantibodies-associated haemolytic uraemic syndrome. Nephrol Dial Transplant. 2008;23(6):2088\u201390.","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"2334_CR29","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1056\/NEJMc0808527","volume":"360","author":"J N\u00fcrnberger","year":"2009","unstructured":"N\u00fcrnberger J, Philipp T, Witzke O, Saez AO, Vester U, Baba HA, et al. Eculizumab for atypical hemolytic\u2013uremic syndrome. N Engl J Med. 2009;360(5):542\u20134.","journal-title":"N Engl J Med"},{"issue":"1","key":"2334_CR30","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","volume":"31","author":"C Loirat","year":"2016","unstructured":"Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, Coppo R, Emma F, Johnson S, Karpman D, Landau D. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016;31(1):15\u201339.","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"2334_CR31","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s00467-017-3612-9","volume":"32","author":"A Hackl","year":"2017","unstructured":"Hackl A, Ehren R, Kirschfink M, Zipfel PF, Beck BB, Weber LT, et al. Successful discontinuation of eculizumab under immunosuppressive therapy in DEAP-HUS. Pediatr Nephrol. 2017;32(6):1081\u20137.","journal-title":"Pediatr Nephrol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-019-2334-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13256-019-2334-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-019-2334-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T01:24:05Z","timestamp":1610414645000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-019-2334-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,13]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2334"],"URL":"https:\/\/doi.org\/10.1186\/s13256-019-2334-y","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,13]]},"assertion":[{"value":"26 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient\u2019s legal guardian for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11"}}